Browse GLB1

Summary
SymbolGLB1
Namegalactosidase, beta 1
Aliases ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Lysosome ; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm, perinuclear region Note=Localized to the perinuclear area of the cytoplasm but not to lysosomes.
Domain PF13364 Beta-galactosidase jelly roll domain
PF01301 Glycosyl hydrolases family 35
Function

Isoform 1: Cleaves beta-linked terminal galactosyl residues from gangliosides, glycoproteins, and glycosaminoglycans. ; FUNCTION: Isoform 2: Has no beta-galactosidase catalytic activity, but plays functional roles in the formation of extracellular elastic fibers (elastogenesis) and in the development of connective tissue. Seems to be identical to the elastin-binding protein (EBP), a major component of the non-integrin cell surface receptor expressed on fibroblasts, smooth muscle cells, chondroblasts, leukocytes, and certain cancer cell types. In elastin producing cells, associates with tropoelastin intracellularly and functions as a recycling molecular chaperone which facilitates the secretions of tropoelastin and its assembly into elastic fibers.

> Gene Ontology
 
Biological Process GO:0005996 monosaccharide metabolic process
GO:0006012 galactose metabolic process
GO:0006022 aminoglycan metabolic process
GO:0006026 aminoglycan catabolic process
GO:0006027 glycosaminoglycan catabolic process
GO:0006643 membrane lipid metabolic process
GO:0006664 glycolipid metabolic process
GO:0006665 sphingolipid metabolic process
GO:0006687 glycosphingolipid metabolic process
GO:0006790 sulfur compound metabolic process
GO:0016052 carbohydrate catabolic process
GO:0019318 hexose metabolic process
GO:0019320 hexose catabolic process
GO:0019388 galactose catabolic process
GO:0030203 glycosaminoglycan metabolic process
GO:0042339 keratan sulfate metabolic process
GO:0042340 keratan sulfate catabolic process
GO:0044262 cellular carbohydrate metabolic process
GO:0044273 sulfur compound catabolic process
GO:0044282 small molecule catabolic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0044724 single-organism carbohydrate catabolic process
GO:0046365 monosaccharide catabolic process
GO:1901136 carbohydrate derivative catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1903509 liposaccharide metabolic process
GO:1903510 mucopolysaccharide metabolic process
Molecular Function GO:0004308 exo-alpha-sialidase activity
GO:0004553 hydrolase activity, hydrolyzing O-glycosyl compounds
GO:0004565 beta-galactosidase activity
GO:0015925 galactosidase activity
GO:0016798 hydrolase activity, acting on glycosyl bonds
GO:0016936 galactoside binding
GO:0016997 alpha-sialidase activity
Cellular Component GO:0005775 vacuolar lumen
GO:0043202 lysosomal lumen
> KEGG and Reactome Pathway
 
KEGG hsa04142 Lysosome
hsa00052 Galactose metabolism
hsa00511 Other glycan degradation
hsa00531 Glycosaminoglycan degradation
hsa00600 Sphingolipid metabolism
hsa00604 Glycosphingolipid biosynthesis - ganglio series
hsa01100 Metabolic pathways
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-446193: Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-1660662: Glycosphingolipid metabolism
R-HSA-2024096: HS-GAG degradation
R-HSA-1638091: Heparan sulfate/heparin (HS-GAG) metabolism
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-2022857: Keratan sulfate degradation
R-HSA-1638074: Keratan sulfate/keratin metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-392499: Metabolism of proteins
R-HSA-6798695: Neutrophil degranulation
R-HSA-597592: Post-translational protein modification
R-HSA-4085001: Sialic acid metabolism
R-HSA-428157: Sphingolipid metabolism
R-HSA-446219: Synthesis of substrates in N-glycan biosythesis
Summary
SymbolGLB1
Namegalactosidase, beta 1
Aliases ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GLB1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between GLB1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29653690colon carcinomaPromote immunityWe used a pCMV-LacZ plasmid (expressing β-galactosidase) and a pcDNA-hNIS plasmid (expressing the human sodium/iodide symporter [hNIS] gene) as non-secreted visual-imaging markers.
Summary
SymbolGLB1
Namegalactosidase, beta 1
Aliases ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GLB1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGLB1
Namegalactosidase, beta 1
Aliases ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GLB1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1980.461
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4360.844
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.020.991
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1910.497
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0240.992
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4050.896
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0980.816
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0130.994
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2760.891
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1260.941
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5610.825
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0840.251
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GLB1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGLB1
Namegalactosidase, beta 1
Aliases ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GLB1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGLB1
Namegalactosidase, beta 1
Aliases ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GLB1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GLB1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGLB1
Namegalactosidase, beta 1
Aliases ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GLB1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGLB1
Namegalactosidase, beta 1
Aliases ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GLB1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGLB1
Namegalactosidase, beta 1
Aliases ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GLB1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGLB1
Namegalactosidase, beta 1
Aliases ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GLB1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.